机器人辅助与腹腔镜微创治疗 I 期子宫内膜癌的比较。
Robot-assisted versus laparoscopic minimally invasive surgery for the treatment of stage I endometrial cancer.
机构信息
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, MN, United States of America.
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, MN, United States of America.
出版信息
Gynecol Oncol. 2022 May;165(2):347-352. doi: 10.1016/j.ygyno.2022.03.007. Epub 2022 Mar 18.
OBJECTIVE
Recent reports in both cervical and endometrial cancer suggest that minimally invasive surgery (MIS) had an unanticipated negative impact on long-term clinical outcomes, including recurrence and death. Given increasing use of robotic surgery since the LAP2 trial, we sought to compare the intermediate and long-term outcomes between those who underwent robotic surgery or laparoscopy for Stage I endometrial cancer.
METHODS
We performed a retrospective review of patients from a single, large, academic, urban practice who underwent either laparoscopic or robot-assisted MIS (RA-MIS) for the treatment of endometrial carcinoma between 2006 and 2016, ensuring at least 5 years of potential follow-up. To adjust for differences in confounding variables between groups, propensity score-based inverse probability of treatment weighting (IPTW) was performed. Overall and recurrence-free survival were compared using Cox proportional hazards regression models adjusting for confounding weights.
RESULTS
1027 patients were included; 461 received laparoscopy and 566 received RA-MIS. RA-MIS use increased steadily during the study window, which resulted in longer mean surveillance in laparoscopy group (median 8.7 years versus 6.3 years, p < 0.001). RA-MIS was associated poorer recurrence-free (HR: 1.41, 95% CI: 1.12, 1.77) and overall survival (HR: 1.39, 95% CI: 1.06, 1.83). Disease-specific survival was also poorer in the RA-MIS group (HR: 3.51, 95% CI: 2.19, 5.63). Among those who recurred, median time to first recurrence was shorter in the RA-MIS group than the laparoscopy group (16.3 vs. 28.7 months, p = 0.07).
CONCLUSION
RA-MIS was associated with poorer long-term patient outcomes. Our data in this lower-risk population indicate relevant clinical endpoints may be occurring during intermediate and long-term follow-up windows. These findings support a prospective evaluation of the long-term outcomes of RA-MIS.
目的
最近在宫颈癌和子宫内膜癌中的报告表明,微创手术(MIS)对长期临床结果产生了意外的负面影响,包括复发和死亡。鉴于 LAP2 试验后机器人手术的使用增加,我们试图比较接受机器人手术或腹腔镜手术治疗 I 期子宫内膜癌的患者的中期和长期结果。
方法
我们对单一大型学术城市实践中接受腹腔镜或机器人辅助微创手术(RA-MIS)治疗子宫内膜癌的患者进行了回顾性研究,时间为 2006 年至 2016 年,至少有 5 年的潜在随访时间。为了调整组间混杂变量的差异,采用基于倾向评分的逆概率治疗加权(IPTW)。使用 Cox 比例风险回归模型比较总生存率和无复发生存率,并调整混杂权重。
结果
共纳入 1027 例患者,其中 461 例接受腹腔镜手术,566 例接受 RA-MIS。在研究期间,RA-MIS 的使用率稳步增加,导致腹腔镜组的中位随访时间更长(中位数 8.7 年与 6.3 年,p<0.001)。RA-MIS 与无复发生存率(HR:1.41,95%CI:1.12,1.77)和总生存率(HR:1.39,95%CI:1.06,1.83)降低相关。RA-MIS 组的疾病特异性生存率也较差(HR:3.51,95%CI:2.19,5.63)。在复发的患者中,RA-MIS 组的首次复发中位时间短于腹腔镜组(16.3 个月与 28.7 个月,p=0.07)。
结论
RA-MIS 与患者的长期预后较差相关。我们在低风险人群中的数据表明,相关的临床终点可能发生在中期和长期随访期间。这些发现支持对 RA-MIS 的长期结果进行前瞻性评估。
相似文献
Int J Gynecol Cancer. 2020-4-9
Am J Obstet Gynecol. 2019-7-6
引用本文的文献
本文引用的文献
CA Cancer J Clin. 2021-1
N Engl J Med. 2018-10-31
N Engl J Med. 2018-10-31